List of Excipients in Branded Drug PIOGLITAZONE HCL AND METFORMIN HCL

« Back to Dashboard

Generic Drugs Containing PIOGLITAZONE HCL AND METFORMIN HCL

Company	Ingredient	NDC	Excipient
Torrent Pharmaceuticals Limited	pioglitazone hcl and metformin hcl	13668-280	CELLULOSE, MICROCRYSTALLINE
Torrent Pharmaceuticals Limited	pioglitazone hcl and metformin hcl	13668-280	CROSCARMELLOSE SODIUM
Torrent Pharmaceuticals Limited	pioglitazone hcl and metformin hcl	13668-280	HYPROMELLOSE 2910
Torrent Pharmaceuticals Limited	pioglitazone hcl and metformin hcl	13668-280	MAGNESIUM STEARATE
Torrent Pharmaceuticals Limited	pioglitazone hcl and metformin hcl	13668-280	POLYETHYLENE GLYCOL 8000

What are the Most Frequently-Used Excipients in PIOGLITAZONE HCL AND METFORMIN HCL?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	CROSCARMELLOSE SODIUM
1	HYPROMELLOSE 2910
1	MAGNESIUM STEARATE
1	POLYETHYLENE GLYCOL 8000

Pioglitazone HCl and Metformin HCl Excipient Strategy and Commercial Opportunities

Last updated: October 7, 2026

Pioglitazone HCl/metformin HCl is a mature fixed-dose combination with limited primary patent barriers and substantial formulation opportunity. The core development challenge is combining a high-dose, hydrophilic, hygroscopic metformin salt with a low-dose, poorly soluble pioglitazone salt while meeting dissolution, content-uniformity, stability, and bioequivalence requirements. The strongest commercial opportunities are low-cost generic products, modified-release presentations, differentiated tablets, and markets where type 2 diabetes treatment remains underpenetrated.

What is the commercial status of pioglitazone HCl and metformin HCl products?

Pioglitazone is a thiazolidinedione insulin sensitizer. Metformin is a biguanide that reduces hepatic glucose production and improves insulin sensitivity. The combination provides complementary pharmacology but carries safety and tolerability considerations associated with both components.

Product	Active ingredients	Typical strengths	Release type	Commercial status
Actoplus Met	Pioglitazone HCl/metformin HCl	15/500 mg, 15/850 mg, 15/1000 mg	Immediate release	Originator product; generic competition exists
Actoplus Met XR	Pioglitazone HCl/metformin HCl	15/1000 mg	Extended release	Originator modified-release product; generic development opportunity depends on current reference-product and regulatory status
Generic fixed-dose tablets	Pioglitazone HCl/metformin HCl	Commonly 15/500 mg, 15/850 mg, 15/1000 mg	Immediate release	Available in multiple jurisdictions
Separate-component therapy	Pioglitazone plus metformin	Multiple strengths	Immediate or extended release	Major competitive alternative

The U.S. label for Actoplus Met identifies the combination as an adjunct to diet and exercise for adults with type 2 diabetes when treatment with both agents is appropriate [1]. Pioglitazone is also available as a separate product, while metformin is available in immediate-release and extended-release forms.

The combination is less commercially attractive in markets dominated by newer GLP-1 receptor agonists, SGLT2 inhibitors, and DPP-4 inhibitors. It remains relevant where price, oral administration, generic availability, and insulin-sensitizing therapy drive prescribing.

What excipient problems must a formulation solve?

The formulation must accommodate two salts with materially different physicochemical profiles.

Metformin HCl

Metformin HCl is highly water soluble and is administered at a high dose. The main formulation risks are:

• High tablet mass.
• Hygroscopicity and moisture uptake.
• Poor powder flow.
• Variable compactibility.
• Sticking and picking during compression.
• Potential dissolution acceleration or destabilization from excess porosity.
• Difficulty achieving content uniformity when combined with a low-dose active ingredient.

A conventional metformin tablet often requires substantial diluent and compression optimization. In a combination product, the metformin fraction dominates tablet weight and can limit the amount of functional excipient available for pioglitazone.

Pioglitazone HCl

Pioglitazone HCl is used at a much lower dose than metformin. Its key formulation issues are:

• Low dose relative to the total tablet mass.
• Risk of poor content uniformity.
• Limited aqueous solubility compared with metformin.
• Sensitivity of dissolution to particle size, wetting, granulation, and lubricant concentration.
• Potential segregation from the higher-dose metformin fraction.

The formulation should treat pioglitazone distribution as a high-priority process-control issue. Geometric dilution, ordered mixing, separate granulation, or a bilayer architecture may be required depending on the target product profile.

Which excipients are suitable for immediate-release tablets?

A practical immediate-release formulation typically uses a combination of diluents, binders, disintegrants, glidants, lubricants, and moisture-control measures.

Functional role	Candidate excipients	Formulation rationale
Diluent	Microcrystalline cellulose, lactose monohydrate, anhydrous lactose, dibasic calcium phosphate	Provides bulk and improves compactibility
Binder	Povidone, copovidone, hydroxypropyl cellulose, pregelatinized starch	Improves granule strength and tablet hardness
Disintegrant	Croscarmellose sodium, crospovidone, sodium starch glycolate	Supports rapid breakup and dissolution
Glidant	Colloidal silicon dioxide	Improves flow and reduces die-filling variability
Lubricant	Magnesium stearate, sodium stearyl fumarate	Controls ejection force and sticking
Wetting aid	Poloxamer or low-level sodium lauryl sulfate	May improve pioglitazone wetting, subject to tolerability and regulatory review
Film former	Hypromellose, polyvinyl alcohol, polyethylene glycol	Supports coating, identification, moisture protection, and swallowability
Moisture barrier	Opadry-type systems, polyvinyl alcohol-based coatings	Reduces environmental moisture ingress

Microcrystalline cellulose is often useful because it improves compactibility without materially increasing water activity. Lactose may improve tablet processing but requires compatibility assessment, particularly where moisture, reducing-sugar reactivity, or prolonged storage is relevant. Dibasic calcium phosphate can improve hardness and reduce hygroscopicity but may alter dissolution and increase tablet density.

Crospovidone is often attractive where rapid disintegration is required without excessive swelling. Croscarmellose sodium can also work, but its performance may be more sensitive to compression force and formulation water content.

Magnesium stearate should be optimized carefully. Over-lubrication can reduce tablet tensile strength and retard dissolution, particularly when the formulation relies on hydrophobic surface films. Sodium stearyl fumarate is a potential alternative where lower hydrophobicity or improved lubrication robustness is needed.

What formulation architecture is best for pioglitazone/metformin tablets?

Single-blend direct compression

Direct compression offers the lowest manufacturing complexity and cost. It is suitable when both actives and excipients have compatible flow, density, particle-size distribution, and compression behavior.

The principal risk is segregation. Metformin HCl represents most of the tablet mass, while pioglitazone HCl is present at a low dose. Differences in particle size or density can produce assay variability. Direct compression is most viable when:

• Active-particle sizes are controlled.
• Pioglitazone is preblended with a small quantity of carrier.
• The blend has low segregation potential.
• Compression is monitored through weight and content-uniformity controls.
• The coating process does not introduce additional variability.

Wet granulation

Wet granulation can improve flow, reduce segregation, and increase tablet strength. It may be useful where metformin powder behavior is poor.

The risks include:

• Moisture exposure.
• Longer processing time.
• Potential impact on pioglitazone dissolution.
• Greater scale-up complexity.
• Drying-related variability.

A low-water or solvent-controlled process may be preferable where moisture uptake is a major concern. The binder concentration should be controlled because excessive granule strength can delay disintegration.

Dry granulation

Roller compaction can reduce water exposure and improve flow. It is a strong option for moisture-sensitive or highly hygroscopic blends. The process must control ribbon density, granule-size distribution, fines generation, and recompactability.

Excessive compaction may produce hard granules that dissolve slowly. Fines may also increase segregation or tablet-weight variability.

Bilayer or multilayer tablets

A bilayer tablet can separate the two active ingredients physically. It is technically attractive when the actives require different granulation conditions or when pioglitazone content uniformity is difficult to control in a single blend.

Advantages include:

• Better control of low-dose pioglitazone distribution.
• Independent optimization of each active layer.
• Opportunity to combine immediate-release and extended-release behavior.
• Stronger process differentiation.

Disadvantages include:

• Higher equipment cost.
• More complex scale-up.
• Layer-weight and cross-contamination controls.
• Greater risk of interface defects, capping, and delamination.
• More complex regulatory comparability requirements.

For a cost-focused generic, a bilayer platform may be commercially justified only if it produces a meaningful bioequivalence, stability, or manufacturing advantage.

What excipient strategy is appropriate for extended-release products?

Metformin extended-release products often use hydrophilic matrix systems based on hypromellose, polyethylene oxide, or related polymers. Pioglitazone may remain relatively rapidly available while metformin is released over an extended period, but the final release profile must reflect the reference product.

A matrix system may include:

• High-viscosity hypromellose for gel formation.
• Low-viscosity hypromellose for release tuning.
• Polyethylene oxide for swelling and erosion control.
• Microcrystalline cellulose as a structural diluent.
• Colloidal silicon dioxide for flow.
• Magnesium stearate or sodium stearyl fumarate as lubricant.
• Functional film coating for appearance and moisture protection.

The key development variables are polymer grade, polymer concentration, tablet hardness, compression force, tablet geometry, and dissolution-medium sensitivity.

A formulation intended to be bioequivalent to a reference extended-release product should be evaluated across multiple pH conditions and agitation rates. In vitro release should not be optimized only against a single dissolution method. Alcohol-dose-dumping risk, food effects, and fed-state performance may also matter for modified-release products.

What manufacturing and process controls create commercial value?

The commercial value of the product depends heavily on process robustness because the combination is a high-volume, price-sensitive generic.

Critical quality attributes include:

• Assay of each active ingredient.
• Content uniformity for pioglitazone.
• Tablet weight and thickness.
• Hardness and friability.
• Disintegration.
• Dissolution of each active.
• Water content.
• Degradation products.
• Blend uniformity.
• Coating weight gain.
• Stability under high-temperature and high-humidity conditions.

Critical process parameters include:

• Milling and sieve distribution.
• Order of addition.
• Blend time and speed.
• Granulation endpoint.
• Drying temperature and endpoint.
• Roller-compaction force, where applicable.
• Lubrication time.
• Compression force.
• Coating inlet temperature and spray rate.

A moisture-barrier film coating can reduce metformin-related stability risk, but the coating should not materially delay disintegration or alter dissolution. Packaging may be as important as the tablet formulation. High-density polyethylene bottles with desiccant or alu-alu blister packaging can support regional markets with elevated humidity.

What regulatory pathways apply to pioglitazone/metformin products?

The product is a small-molecule combination, not a biologic. Biosimilar regulation does not apply.

505(j) ANDA pathway

A conventional generic can generally pursue an abbreviated new drug application if it matches the reference product in dosage form, strength, route of administration, and release characteristics. The applicant must establish pharmaceutical equivalence and bioequivalence and address applicable product-specific guidance.

For immediate-release products, comparative pharmacokinetic studies may be required for both pioglitazone and metformin. The exact design depends on the reference product and FDA requirements.

505(b)(2) pathway

A 505(b)(2) application may be relevant for:

• A new extended-release profile.
• A novel dosage form.
• A bilayer architecture with a distinct clinical or pharmacokinetic profile.
• A product with formulation changes that cannot fit comfortably within an ANDA framework.

This pathway can support differentiated products but usually carries greater clinical, regulatory, and development cost.

FDA status and Orange Book considerations

Actoplus Met and Actoplus Met XR are FDA-recognized prescription products. The Orange Book identifies reference-listed drugs, patent certifications, exclusivity information, and marketing status [2]. The product’s principal commercial barriers are no longer expected to arise from the original pioglitazone composition-of-matter patent estate.

Applicants must still review current Orange Book listings, discontinued-product status, applicable patents, exclusivity periods, and FDA product-specific guidance before filing. A listed product’s commercial availability and regulatory reference status should not be inferred solely from historical approval records.

When does pioglitazone/metformin lose exclusivity?

The original pioglitazone exclusivity period has expired in the United States. Pioglitazone generic competition has been established for many years, and fixed-dose pioglitazone/metformin products are also available from generic manufacturers in several markets.

The relevant barriers now include:

Barrier	Current commercial relevance
Original compound patents	Generally expired
Original brand exclusivity	Expired
Immediate-release formulation patents	Limited relevance where expired or nonblocking
Extended-release formulation patents	Must be reviewed product by product
Method-of-use patents	May affect labeling strategy but are less likely to block broad generic entry if expired
Regulatory exclusivity	Depends on product, jurisdiction, and current listing
Manufacturing know-how	Still relevant for cost, yield, stability, and bioequivalence
Trademark and trade dress	Requires separate clearance

Patent expiration does not eliminate all launch risk. A generic applicant must assess listed patents, Paragraph IV certification exposure, pediatric extensions, litigation, settlement terms, and jurisdiction-specific patent rights.

What Paragraph IV and litigation risks exist?

A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic. For a mature combination product, the most likely patent issues concern:

• Extended-release technology.
• Specific polymer systems.
• Tablet architecture.
• Manufacturing processes.
• Crystalline or polymorphic forms.
• Method-of-use claims.
• Combination dosing regimens.

The litigation risk is generally lower for older immediate-release presentations than for newer modified-release products. A Paragraph IV filing can produce litigation under the Hatch-Waxman Act, potentially creating a 30-month stay of approval under applicable conditions [3].

Settlement agreements may include delayed launch dates, authorized-generic arrangements, licenses, or restrictions tied to specific strengths and formulations. Commercial diligence should distinguish between expired patents, patents listed in the Orange Book, and nonlisted patents that may still support separate litigation.

How strong is the patent estate for pioglitazone HCl/metformin HCl?

The patent estate is weak for conventional immediate-release generic products and potentially stronger for differentiated extended-release or multilayer products.

Product strategy	Patent strength	Development risk	Commercial outlook
Standard 15/500 mg immediate-release tablet	Low	Low to moderate	High price pressure
Standard 15/850 mg immediate-release tablet	Low	Low to moderate	Regional generic opportunity
Standard 15/1000 mg immediate-release tablet	Low	Moderate due to tablet size	Broad demand but margin pressure
Modified-release tablet	Moderate	Moderate to high	Better differentiation
Bilayer tablet	Moderate	High	Potential process and IP differentiation
Sprinkle or dispersible format	Potentially moderate	Moderate	Niche opportunity
Co-packaged separate tablets	Low	Low	Operationally simple, limited differentiation

The strongest defensible position is likely to come from formulation and process patents covering a specific release profile, low-moisture manufacturing process, high-dose tablet architecture, or improved stability package. Broad claims covering the active ingredients themselves are unlikely to provide meaningful protection.

Which commercial opportunities are most attractive?

Low-cost immediate-release generics

The largest opportunity is a reliable, low-cost product in commonly prescribed strengths. Cost advantages can come from:

• Direct compression.
• High-throughput rotary compression.
• Reduced excipient count.
• Standardized film coating.
• High-yield packaging.
• Regional contract manufacturing.

Margin pressure will be significant because several suppliers can produce conventional tablets.

Extended-release products

Extended-release products can command better differentiation if they demonstrate adherence, dosing convenience, or improved gastrointestinal tolerability. The technical and regulatory burden is higher, but the opportunity is more defensible than a basic immediate-release tablet.

High-humidity markets

A formulation and packaging platform optimized for tropical and subtropical markets can create value through superior assay retention, dissolution stability, and shelf life. Moisture-barrier packaging and low-water manufacturing may be commercially important in South Asia, Southeast Asia, Latin America, Africa, and the Middle East.

Hospital and institutional supply

Hospitals and public procurement systems may value:

• Stable supply.
• Low acquisition cost.
• Multiple strengths.
• Simple storage requirements.
• Consistent tablet dimensions.
• Reliable packaging and serialization.

Institutional buyers generally reward manufacturing reliability more than minor formulation differentiation.

Combination therapy for treatment simplification

A fixed-dose tablet can reduce pill burden where clinicians already use both medicines. Commercial positioning should focus on treatment simplification and affordability rather than novel pharmacology.

The product must still address pioglitazone-associated weight gain, edema, heart-failure warnings, fracture risk, and bladder-cancer-related labeling history, as well as metformin-associated gastrointestinal effects and lactic-acidosis contraindications in specific patients [1, 4].

How does pioglitazone/metformin compare with newer diabetes combinations?

Combination category	Main advantage	Main disadvantage	Competitive pressure
Pioglitazone/metformin	Low cost, insulin sensitization, established oral therapy	Weight gain, edema, slower adoption	High
Metformin/SGLT2 inhibitor	Cardiovascular and renal positioning for some agents	Higher cost, genitourinary adverse effects	Strong
Metformin/DPP-4 inhibitor	Weight-neutral profile and tolerability	Lower efficacy and higher cost than older generics	Strong
Metformin/GLP-1 receptor agonist	Greater weight-loss and glycemic potential	Injectable or higher-cost oral therapy	Strong
Metformin/sulfonylurea	Low cost and high glucose-lowering effect	Hypoglycemia and weight gain	Moderate
Metformin alone	Low cost and established first-line use	May not achieve adequate control alone	Baseline competitor

Pioglitazone/metformin is most competitive when affordability and insulin resistance are central considerations. It is less competitive in premium markets where cardiovascular, renal, and weight-loss outcomes drive prescribing.

What generic launch scenarios exist?

Scenario 1: Conventional immediate-release launch

This is the lowest-risk path. The company files a standard generic product in one or more established strengths, uses a conventional excipient system, and competes primarily on price and supply reliability.

Scenario 2: Multi-strength regional launch

The company launches 15/500 mg, 15/850 mg, and 15/1000 mg products across selected jurisdictions. This improves portfolio coverage but increases inventory, stability, and registration costs.

Scenario 3: Extended-release differentiation

The company develops a modified-release product with a stronger formulation story and potentially better commercial protection. The investment requirement and bioequivalence risk are materially higher.

Scenario 4: Contract-manufactured institutional product

A manufacturer supplies a distributor, government tender, or branded-generic company. The opportunity depends on production cost, regulatory approvals, and tender access rather than patent exclusivity.

Key Takeaways

• Pioglitazone HCl/metformin HCl is a mature small-molecule fixed-dose combination with expired core compound exclusivity in major markets.
• Immediate-release products face strong price competition and limited formulation patent protection.
• The principal technical risks are metformin hygroscopicity, high tablet mass, pioglitazone content uniformity, segregation, and dissolution control.
• Direct compression is commercially attractive, but wet or dry granulation may provide better flow and uniformity.
• Bilayer and extended-release systems offer more differentiation but carry higher development and regulatory risk.
• Moisture-resistant excipients, barrier coatings, and protective packaging are important for high-humidity markets.
• Biosimilar risk is not relevant because the product is a small-molecule combination.
• The best opportunities are regional generics, institutional supply, high-humidity stability platforms, and differentiated modified-release products.
• The principal commercial risks are low price, newer diabetes therapies, pioglitazone safety concerns, and competition from separate-component regimens.
• Current Orange Book listings, patents, exclusivity, and Paragraph IV exposure must be assessed for each target strength and formulation before filing.

FAQs

Is pioglitazone HCl/metformin HCl suitable for a direct-compression product?

Yes, but direct compression requires tight control of particle-size distribution, blend uniformity, flow, lubrication, and pioglitazone dilution. Dry granulation may be preferable where flow or segregation is problematic.

Which excipient improves pioglitazone dissolution most effectively?

A universal excipient cannot be identified without formulation screening. Wetting agents, particle-size reduction, porous carriers, and selected disintegrants can improve dissolution, but each may affect stability, bioequivalence, or regulatory acceptability.

Can a generic manufacturer use a bilayer tablet to differentiate the product?

Yes. A bilayer design can separate the two actives and support independent release control. It also increases equipment, process-validation, and scale-up requirements.

Does metformin HCl require moisture-protective packaging?

Usually. Metformin HCl can contribute to moisture uptake and processing variability. A barrier film, desiccant bottle, or high-protection blister may improve shelf-life performance, particularly in humid climates.

Is an extended-release pioglitazone/metformin product commercially stronger than an immediate-release generic?

It can be, because modified release may provide differentiation and higher pricing. The advantage depends on successful bioequivalence, release-profile control, regulatory clearance, and physician demand in the target market.

References

1. U.S. Food and Drug Administration. (2023). Actoplus Met (pioglitazone hydrochloride and metformin hydrochloride) prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2017). Abbreviated new drug application submissions: Refuse-to-receive standards. FDA.

4. U.S. Food and Drug Administration. (2016). Drug safety communication: Updated FDA review concludes that use of pioglitazone may be linked to an increased risk of bladder cancer. FDA.